No blend trials identified yet
No published clinical study of this three peptide blend was identified on PubMed. Evidence comes from each component studied separately. Reported in the cited paper.
SourceResearch Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →

GLOW is a three peptide blend combining GHK-Cu, BPC-157 and TB-500. It is used in regenerative, cosmetic and recovery research contexts, pairing collagen signalling with angiogenesis and actin regulation. The blend itself has no published clinical trial.
Supplier listings
Form
Show prices as
Size
78 listings · GLOW
In stock70mgseen 2w ago
In stock70 mg · 10 vialsseen 2w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 2w ago
In stock70mgseen 7w ago
In stock70mgseen 8w ago
In stock70mgseen 5w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 8w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 5w ago
In stock50mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 3w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 3w ago
In stock70mgseen 7w ago
In stock70mgseen 4w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 8w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 8w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 8w ago
In stock70mgseen 7w ago
In stock70mgseen 4w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70mgseen 7w ago
In stock70 mg · 2 vialsseen 4w ago
In stock90mgseen 7w ago
In stock70mgseen 7w ago
In stock70 mg · 10 vialsseen 7w ago
In stock70 mg · 10 vialsseen 7w ago
Out of stock70mgseen 7w ago
Out of stock70mgseen 7w ago
Overview
GLOW is a three peptide blend combining GHK-Cu, BPC-157 and TB-500. It is used in regenerative, cosmetic and recovery research contexts, pairing collagen signalling with angiogenesis and actin regulation. The blend itself has no published clinical trial.
What the research reports
Outcomes described across the published literature and ongoing study. Read each as research context rather than a promised personal result.
Three separate mechanism blend
Combines collagen and elastin signalling with angiogenic action and actin regulation, covering three separate repair pathways at once. Reported in research settings.
Skin and tissue repair focus
The GHK-Cu component adds a cosmetic dimension that the two repair peptides on their own do not provide. Reported in study settings and not promised as a personal result.
Multi-pathway combination rationale
The three components are studied as acting through non-overlapping mechanisms, collagen signalling, angiogenesis, and actin regulation, which is the stated rationale for combining them. This explains why the blend was formulated, not evidence that the combination produces a greater effect than the parts alone.
Component level study evidence
Each peptide carries its own preclinical record, so the blend inherits the evidence of its parts rather than adding its own. Reported in research settings.
Popular recovery study blend
Widely used in regenerative and athletic recovery settings, which has produced a large body of user reported experience. Reported in research settings.
Clinical evidence
The published record, labeled by strength so you can see what is settled and what is still emerging.
No published clinical study of this three peptide blend was identified on PubMed. Evidence comes from each component studied separately. Reported in the cited paper.
SourceA 2021 case series followed up with 16 of 17 knee pain patients given intra-articular BPC-157, with 14 patients (87.5 percent) reporting significant improvement. Reported in the cited paper.
SourceA randomised trial of 13 patients found topical copper tripeptide produced no significant reduction in redness or wrinkles despite better satisfaction scores. Reported in the cited paper.
SourceInteractions
Questions